Artwork
iconShare
 
Manage episode 523117063 series 2409126
Content provided by The Lancet. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by The Lancet or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.

Franck Morschhauser joins Ben Abbott of The Lancet to discuss the phase 3 EPCORE FL-1 study on epcoritamab, lenalidomide, and rituximab for relapsed or refractory follicular lymphoma, which is being presented at ASH 2025.

  continue reading

702 episodes